[go: up one dir, main page]

CL2022000790A1 - Método para tratar vih con cabotegravir y rilpivirina - Google Patents

Método para tratar vih con cabotegravir y rilpivirina

Info

Publication number
CL2022000790A1
CL2022000790A1 CL2022000790A CL2022000790A CL2022000790A1 CL 2022000790 A1 CL2022000790 A1 CL 2022000790A1 CL 2022000790 A CL2022000790 A CL 2022000790A CL 2022000790 A CL2022000790 A CL 2022000790A CL 2022000790 A1 CL2022000790 A1 CL 2022000790A1
Authority
CL
Chile
Prior art keywords
cabotegravir
rilpivirine
treat hiv
human
pharmaceutically acceptable
Prior art date
Application number
CL2022000790A
Other languages
English (en)
Inventor
Herta Maria Ludovica Crauwels
Susan L Ford
David Andrew Margolis
Stefaan Louis F Rossenu
William Robert Spreen
Solingen-Ristea Rodica Mihaela Van
Peter Evan Owen Williams
Original Assignee
Viiv Healthcare Co
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Co, Janssen Sciences Ireland Unlimited Co filed Critical Viiv Healthcare Co
Publication of CL2022000790A1 publication Critical patent/CL2022000790A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención consiste en métodos para tratar VIH en un humano que los necesita, los cuales comprenden la administración de una cantidad terapéuticamente eficaz de una combinación de cabotegravir o una sal farmacéuticamente aceptable del mismo y rilpivirina o una sal farmacéuticamente aceptable de la misma, a dicho humano.
CL2022000790A 2019-10-01 2022-03-30 Método para tratar vih con cabotegravir y rilpivirina CL2022000790A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962908995P 2019-10-01 2019-10-01
US201962908882P 2019-10-01 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US202063052214P 2020-07-15 2020-07-15

Publications (1)

Publication Number Publication Date
CL2022000790A1 true CL2022000790A1 (es) 2022-11-25

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000790A CL2022000790A1 (es) 2019-10-01 2022-03-30 Método para tratar vih con cabotegravir y rilpivirina

Country Status (11)

Country Link
US (3) US20220347174A1 (es)
EP (1) EP4037661A1 (es)
JP (1) JP7791083B2 (es)
KR (1) KR20220074880A (es)
CN (2) CN118416069A (es)
AU (1) AU2020358156B2 (es)
CA (1) CA3155587A1 (es)
CL (1) CL2022000790A1 (es)
IL (1) IL290716A (es)
MX (1) MX2022003945A (es)
WO (1) WO2021064618A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
WO2023222754A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774750C (en) * 2009-09-22 2017-11-28 Tibotec Pharmaceuticals Treatment and prevention of hiv infection
AU2018304591A1 (en) * 2017-07-21 2020-03-05 Janssen Sciences Ireland Unlimited Company Regimens for treating hiv infections and aids
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
MD3986561T2 (ro) * 2019-06-19 2024-06-30 Viiv Healthcare Uk No 5 Ltd Derivați de pirido[2,3-d]pirimidină сa inhibitori ai replicării virusului imunodeficienței umane

Also Published As

Publication number Publication date
JP7791083B2 (ja) 2025-12-23
US20250302829A1 (en) 2025-10-02
CN114502166A (zh) 2022-05-13
AU2020358156A1 (en) 2022-04-21
US20250302830A1 (en) 2025-10-02
MX2022003945A (es) 2022-04-25
AU2020358156B2 (en) 2024-06-06
WO2021064618A1 (en) 2021-04-08
KR20220074880A (ko) 2022-06-03
IL290716A (en) 2022-04-01
CN118416069A (zh) 2024-08-02
EP4037661A1 (en) 2022-08-10
JP2022550828A (ja) 2022-12-05
CA3155587A1 (en) 2021-04-08
US20220347174A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MX2020001732A (es) Tratamiento de las afecciones del sistema nervioso central.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
MX2022000143A (es) Metodos novedosos.
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2019014024A (es) Tratamiento de los trastornos depresivos.
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CO2018011686A2 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
MX2024002581A (es) Lou064 para el tratamiento de la esclerosis multiple.
CO2020010013A2 (es) Terapia de combinación para tratar o prevenir el cáncer
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131